Howard "Skip" A. Burris, III, MD

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Howard "Skip" A. Burris, III, MD, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the incorporation of biosimilars in oncology.